The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gareev I.F.

Bashkir State Medical University of the Ministry of Health of the Russia, Ufa, Russia

Beylerli O.A.

Bashkir State Medical University of the Ministry of Health of the Russia, Ufa, Russia

Circulating microRNAs as biomarkers: what are perspectives?

Authors:

Gareev I.F., Beylerli O.A.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2018;21(6): 142‑150

DOI: 10.17116/profmed201821061142

Views: 6925

Downloaded: 410

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Gareev IF, Beylerli OA. Circulating microRNAs as biomarkers: what are perspectives?. Russian Journal of Preventive Medicine. 2018;21(6):142‑150. (In Russ.)
https://doi.org/10.17116/profmed201821061142

 
МСФ на ЯМ
Close metadata
Recommended articles:
Diagnostic capa­bilities of circulating microRNA profiles in patients with acute coro­nary syndrome and stable coro­nary artery disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):125-132
Mela­tonin at the health-resort stage of treatment and reha­bilitation in national practice. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(1):55-59
Electroencephalography: features of the obtained data and its applicability in psychiatry. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):31-39
Regu­latory miRNA21, miRNA92, miRNA221 and miRNAlet7 expression in caro­tid and coro­nary athe­rosclerotic plaques. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):245-252
Treatment of atopic dermatitis considering asse­ssment of neurotransmitters in blood. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(4):368-376
Modern scientific and practical approaches to searching for biomarkers of aging. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(3):46-52
Prognostic scale for early dete­ction of various postoperative complications after thoracic aortic surgery: post-hoc analysis of biomarkers. Piro­gov Russian Journal of Surgery. 2024;(10):38-48
New aspe­cts of psoriasis pathogenesis: meta­bolomic profiling in dermatology. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):526-531
Labo­ratory biomarkers for the prognosis of chro­nic heart failure. Labo­ratory Service. 2024;(3):5-16
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48

MicroRNAs are short, non-coding RNAs with a length of 18—25 nucleotides that regulate about one third of the genome at the posttranscriptional level. Due to different types of transport, microRNAs can be detected in biological fluids, such as blood, urine, cerebrospinal fluid, or saliva. In addition, the circulating microRNA profile is a certain part of the cells in which they are modified and secreted in accordance with the physiological or pathological conditions of these cells. Therefore, microRNAs are considered as biomarkers of interest in many diseases. However, one can encounter several problems associated with substantial differences between the procedures of sample processing, the methods of analysis, and especially the strategies of result standardization. This review presents current knowledge of the use of circulating microRNAs as biomarkers in biological fluids, as well as the prospects arising from the fact that the vesicular fractions of circulating microRNAs can be employed to evaluate the state of cells and tissues, which synthesize them.

Keywords:

MicroRNA
biological fluids
biomarkers
pathology

Authors:

Gareev I.F.

Bashkir State Medical University of the Ministry of Health of the Russia, Ufa, Russia

Beylerli O.A.

Bashkir State Medical University of the Ministry of Health of the Russia, Ufa, Russia

List of references:

  1. McGuire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015;4:145-155. https://doi.org/10.1007/s10555-015-9551-7
  2. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56:1733-1741. https://doi.org/10.1373/clinchem.2010.147405
  3. Chim SS, Shing TK, Hung EC, Leung TC, Lau TK, Chiu RW, Lo YM. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008;54:482-490. https://doi.org/10.1373/clinchem.2007.097972
  4. Chen X, Liang H, Zhang J, Zen K, Zhang CY. Horizontal transfer of miRNAs: Molecular mechanisms and clinical applications. Protein Cell. 2012;3:28-37. https://doi.org/10.1007/s13238-012-2003-z
  5. Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, Perez- Hernandez D, Vazquez J, Martin-Cofreces N, Martinez-Herrera DJ, Pascual-Montano A, Mittelbrunn M, Sánchez-Madrid F. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun. 2013;4:2980. https://doi.org/10.1038/ncomms3980
  6. Guay C, Menoud V, Rome S, Regazzi R. Horizontal transfer of exosomal microRNAs transduce apoptotic signals between pancreatic beta-cells. Cell Commun Signal. 2015;13:1. https://doi.org/10.1186/s12964-015-0097-7
  7. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012;12:358-369. https://doi.org/10.1038/nrg3198
  8. Solayman MHM, Langaee T, Patel A, El-Wakeel L, El-Hamamsy M, Badary O. Identification of suitable endogenous normalizers for qRTPCR analysis of plasma microRNA expression in essential hypertension. Mol Biotechnol. 2016;58:179-187. https://doi.org/10.1007/s12033-015-9912-z
  9. Campomenosi P, Gini E, Noonan DM, Poli A, D’Antona P, Dominioni L, Imperatori A. A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer. BMC Biotechnol. 2016;16:60. https://doi.org/10.1186/s12896-016-0292-7
  10. Wang K, Yuan Y, Cho JH, Clarty SM, Baxter D, Galas DJ. Comparing the microRNA spectrum between serum and plasma. PLoS ONE. 2012;7:e41561. https://doi.org/10.1371/journal.pone.0041561
  11. Kim DJ, Linnstaedt S, Palma J, Park JC, Ntrivalas E, Kwak-Kim JY, Gilman-Sachs A, Beaman K, Hastings ML, Martin JN, Duelli DM. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn. 2012;14:71-80. https://doi.org/10.1016/j.jmoldx.2011.09.002
  12. Marzi MJ, Montani F, Carletti RM, Dezi F, Dama E, Bonizzi G, Sandri MT, Rampinelli C, Bellomi M, Maisonneuve P, Spaggiari L, Veronesi G, Bianchi F, Di Fiore PP, Nicassio F. Optimization and standardization of circulating microRNA detection for clinical application: the miR-Test Case. Clin Chem. 2016;62:743-754. https://doi.org/10.1373/clinchem.2015.251942
  13. Koberle V, Pleli T, Schmithals C, Alonso EA, Haupenthal J, Bonig H, Peveling-Oberhag J, Biondi RM, Zeuzem S, Kronenberger B, Waidmann O, Piiper A. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One. 2013;8:e75184. https://doi.org/10.1371/journal.pone.0075184
  14. El-Khoury V, Pierson S, Kaoma T, Bernardin F, Berchem G. Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. Sci Rep. 2016;6:19529. https://doi.org/10.1038/srep19529
  15. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50:298-301. https://doi.org/10.1016/j.ymeth.2010.01.032
  16. Chen F, Zhang W, Liang Y, Huang J, Li K, Green CD, Liu J , Zhang G, Zhou B, Yi X, Wang W, Liu H, Xu X, Wang J. Transcriptome and network changes in climbers at extreme altitudes. PLoS One. 2012;7:e31645. https://doi.org/10.1371/journal.pone.0031645
  17. Li Y, Zhang L, Liu F, Xiang G, Jiang D, Pu X. Identification of endogenous controls for analyzing serum exosomal miRNA in patients with hepatitis B or hepatocellular carcinoma. Dis Markers. 2015;2015:893594. https://doi.org/10.1155/2015/893594
  18. Yuan H, Mischoulon D, Fava M, Otto MW. Circulating microRNAs as biomarkers for depression: many candidates, few finalists. J Affect Disord. 2018;233:68-78. https://doi.org/10.1016/j.jad.2017.06.058
  19. Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. 2016;4312-4320. https://doi.org/10.1038/onc.2015.492
  20. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford KL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672-675. https://doi.org/10.1111/j.1365-2141.2008.07077.x
  21. Ono S, Lam S, Nagahara M, Hoon DS. Circulating microRNA biomarkers as liquid biopsy for cancer patients: pros and cons of current assays. J Clin Med. 2015;4:1890-1907. https://doi.org/10.3390/jcm4101890
  22. Moyer VA. Preventive Services Task Force Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330-338. https://doi.org/10.7326/M13-2771
  23. Barger JF, Nana-Sinkam SP. MicroRNA as tools and therapeutics in lung cancer. Respir Med. 2015;109:803-812. https://doi.org/10.1016/j.rmed.2015.02.006
  24. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 2012;29:618-626. https://doi.org/10.1007/s12032-011-9923-y
  25. Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, Russo A, Giordano A, Adamo V. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to Pemetrexed-based chemotherapy in advanced Non-Small Cell Lung Cancer. J Cell Physiol. 2014;229:97-99. https://doi.org/10.1002/jcp.24422
  26. Denis H, Van Grembergen O, Delatte B, Dedeurwaerder S, Putmans P, Calonne E, Rothé F, Sotiriou C, Fuks F, Deplus R. MicroRNAs regulate KDM5 histone demethylases in breast cancer cells. Mol BioSyst. 2016;12:404-413. https://doi.org/10.1039/c5mb00513b
  27. Han M, Wang F, Gu Y, Pei X, Guo G, Yu C, Li L, Zhu M, Xiong Y, Wang Y. MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-β pathways. Oncol Rep. 2016;35:73-80. https://doi.org/10.3892/or.2015.4360
  28. Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu , Fujiwara Y1, Kinoshita T, Tamura K, Ochiya T. A novel combination of serum microRNAs for detecting breast cancer in the early stage. Cancer Sci. 2016;107:326-334. https://doi.org/10.1111/cas.12880
  29. Sahlberg KK, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale A, Santarpia L. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res. 2015;21:1207-1214. https://doi.org/10.1158/1078-0432.CCR-14-2011
  30. Bonci D, Coppola V, Patrizii M, Addario A, Cannistraci A, Francescangeli F, Pecci R, Muto G, Collura D, Bedini R, Zeuner A,Valtieri M, Sentinelli S, MS Benassi, Gallucci M, Carlini P, Piccolo P, De Maria R. A microRNA code for prostate cancer metastasis. Oncogene. 2016;35:1180-1192. https://doi.org/10.1038/onc.2015.176
  31. Kelly BD, Miller N, Sweeney KJ, Durkan GC, Rogers E, Walsh K, Kerin M. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group. J Clin Med. 2015;4:1369-1379. https://doi.org/10.3390/jcm4071369
  32. Bryant R, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106:68-774. https://doi.org/10.1038/bjc.2011.595
  33. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y, Lin TY. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25:1674-1680. https://doi.org/10.1111/j.1440-1746.2010.06417.x
  34. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118-126. https://doi.org/10.1002/ijc.25007
  35. Ng EK, Chong WW, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58:1375-1381. https://doi.org/10.1136/gut.2008.167817
  36. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6:e17745. https://doi.org/10.1371/journal.pone.0017745
  37. Kuo TY, His E, Yang IP, Tsai PC, Wang JY, Juo SHH. Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS One. 2012;7:e31587. https://doi.org/10.1371/journal.pone.0031587
  38. De Smaele E, Ferretti E, Gulino A. MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res. 2010;100-111. https://doi.org/10.1016/j.brainres.2010.03.103
  39. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470-1476. https://doi.org/10.1038/ncb1800
  40. Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, Di Rocco C, Riccardi R, Giangaspero F, Farcomeni A, Nofroni I, Laneve P, Gioia U, Caffarelli E, Bozzoni I, Screpanti I, Gulino A. MicroRNA profiling in human medulloblastoma. Int J Cancer. 2009;124:568-577. https://doi.org/10.1002/ijc.23948
  41. Nazari-Jahantigh M, Egea V, Schober A, Weber C. MicroRNA-specific regulatory mechanisms in atherosclerosis. J Mol Cell Cardiol. 2015;89:35-41. https://doi.org/10.1016/j.yjmcc.2014.10.021
  42. Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem. 2012;58:559-567. https://doi.org/10.1373/clinchem.2011.173823
  43. Long G, Wang F, Duan Q, Chen F, Yang S, Gong W, Wang Y, Chen C, Dao Wang DW. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci. 2012;8:811. https://doi.org/10.7150/ijbs.4439
  44. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, Kempf T, Wollert KC, Thum T. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51:872-875. https://doi.org/10.1016/j.yjmcc.2011.07.011
  45. Otsuka M, Kishikawa T, Yoshikawa T, Yamagami M, Ohno M, Takata A, Shibata C, Ishibashi R, Koike K. MicroRNAs and liver disease. J Hum Genet. 2016. https://doi.org/10.1038/jhg.2016.53
  46. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M, Sun S. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemicalrelated hepatic diseases. Clin Chem. 2010;56:1830-1838. https://doi.org/10.1373/clinchem.2010.147850
  47. Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol. 2015;4:57. https://doi.org/10.5527/wjn.v4.i1.57
  48. Szeto CC, Ching-Ha KB, Ka-Bik L, Mac-Moune LF, Cheung-Lung CP, Gang W, Kai-Ming C, Kam-Tao LP. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis Mark. 2012;33:137-144. https://doi.org/10.3233/DMA-2012-0914
  49. Szeto CC. Urine miRNA in nephrotic syndrome. Clin Chim Acta. 2014;436:308-313. https://doi.org/10.1016/j.cca.2014.06.016
  50. Matz M, Fabritius K, Lorkowski C, Durr M, Gaedeke J, Durek P, Grün JR, Goestemeyer A, Bachmann F, Wu K, Rudolph B, Schmidt D, Weber U, Haftmann C, Unterwalder N, Lachmann N, Radbruch A, Neumayer HH, Mashreghi MF, Budde K. Identification of T cell-mediated vascular rejection after kidney transplantation by the combined measurement of 5 specific microRNAs in blood. Transplantation. 2015;100:898-907. https://doi.org/10.1097/TP.0000000000000873
  51. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137-149. https://doi.org/10.1016/j.diabres.2013.11.002
  52. Osipova J, Fischer DC, Dangwal S, Volkmann I, Widera C, Schwarz K, Lorenzen JM, Schreiver C, Jacoby U, Heimhalt M, Thum T, Haffner D. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J Clin Endo Metab. 2014;9:E1661-E1665. https://doi.org/10.1210/jc.2013-3868
  53. Marchand L. Au-dela` de la ge´ne´ tique conventionnelle : micro-ARN et diabe` te. Med Mal Metab. 2014;8:324-326.
  54. Zhu H, Leung SW. Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia. 2015;58:900-911. https://doi.org/10.1007/s00125-015-3510-2
  55. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810-817. https://doi.org/10.1161/CIRCRESAHA.110.226357
  56. Zhao C, Dong J, Jiang T, Shi Z, Yu B, Zhu Y, Chen D, Xu J, Huo R, Dai J, Xia Y, Pan S, Hu Z, Sha J. Early secondtrimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One. 2011;6:e23925. https://doi.org/10.1371/journal.pone.0023925

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.